7/102 sources · 2 publishersUpdated Nov 17, 18:43 UTC
FDA approves GSK lung cancer drug acquired through Nuvalent deal
The U.S. Food and Drug Administration granted accelerated approval to GSK’s neladalkib for lung cancer. The kinase inhibitor came through GSK’s $10.6B acquisition of Nuvalent, linking the regulatory decision to that transaction.
Why it matters
The approval permits U.S. commercialization of the therapy and supports Bloomberg’s characterization that it validates GSK’s Nuvalent acquisition.
Key facts
- 1Neladalkib received accelerated approval from the FDA for lung cancer treatment. seekingalpha.com
- 2GSK acquired Nuvalent for $10.6B. seekingalpha.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.